Publications by authors named "L Devriese"
Article Synopsis
- The study examines how impaired liver function affects the toxicity of the anticancer drug paclitaxel, specifically focusing on hematological complications, dose modifications, and overall survival rates in cancer patients.
- It analyzes data from 569 patients treated at the University Medical Centre Utrecht between 2011 and 2022, comparing those with normal and impaired liver function based on specific medical criteria.
- Results show that patients with liver impairment experienced significantly higher risks of severe neutropenia and leukopenia, required more dose modifications, and had poorer overall survival in cases of inoperable esophageal and advanced ovarian cancers.
Background: Patients with head and neck squamous cell carcinoma (HNSCC) face several physical, emotional, and psychological challenges throughout treatment. Cisplatin-based chemoradiotherapy (CRT) is an effective but toxic treatment, with an increased risk for toxicities in patients with low skeletal muscle mass (SMM). Consequently, these patients are anticipated to experience greater treatment-related difficulties.
View Article and Find Full Text PDFBackground: Sinonasal squamous cell carcinoma is known for its rarity and poor prognosis. This study aims to investigate the trends in the incidence of sinonasal squamous cell carcinoma in the Netherlands and to analyze patient characteristics and treatment practices in order to assess their relation with patient outcomes.
Methods: In this prospectively designed population-based cohort study, all patients diagnosed with sinonasal squamous cell carcinoma between 2008 and 2021 in the Netherlands were included.
Radiotherapy (RT) is a standard treatment for head and neck cancer (HNC) and chemoradiotherapy (CRT) is indicated for patients with locally advanced disease. Toxicities during treatment are common and can lead to early cessation of chemotherapy and radiotherapy (RT) interruptions, which can affect oncologic outcomes. Skeletal muscle mass (SMM) is a new biomarker to predict toxicities and overall survival.
View Article and Find Full Text PDFThe association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.
Head Neck
January 2025
Introduction: Patients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin-based chemoradiotherapy (CRT) frequently experience irreversible sensorineural hearing loss (SNHL). Patients with low lumbar skeletal muscle index (LSMI) may experience higher serum peak dosages of cisplatin. This study investigated whether pre-treatment low LSMI is associated with increased SNHL upon cisplatin-based CRT.
View Article and Find Full Text PDF